High-dose Opioid Therapy: In regards to Mr./Mrs. X's opioid use, given that their total daily dosage exceeds 100mg-equivalents of Morphine Sulfate per day they are at a 9 fold increase risk of adverse drug-related events compared with age-matched controls. (1) Moreover, this risk is not theoretical but real as our state ranks X nationally in prescription opioid abuse.(2)
Conversely, with respect to the potential benefits of high dose opioid therapy in this setting, given Mr./Mrs. X's - activity level, BMI, employment status, self-reported pain scale of 10/10 in spite of high dosages, ODI/NDI, disability status, smoking status, Zung depression scale, THC status, etc,- it would appear that their high dose opioid trial has conferred little or no functional benefit. As a result of this weighing of the risks vs benefits I would recommend either a taper of opioids to safer level - below 100mg/equiv Morphine per day - or weaning off opioids entirely.
Unfortunately, while said taper is certainly in the patient's best interests, it is not likely to be endorsed by Mr.Mrs. X. Indeed, my clear impression is that that Mr./Mrs. X is currently pre-contemplative about either opioid weaning or meaningful behavioral changes aimed at adopting a healthier life-style and bolstering their coping skills. Because of this I would recommend concurrent treatment with a licensed psychologist/addictionologist to address coping skills, depression, fear-avoidance, etc, at the outset of the opioid wean.
If Dr. X would like assistance with the weaning regimen I am willing to provide additional advice and support.
Thank you for this consultation. Should you have any questions regarding Mr./Mrs. X please do not hesitate to contact me directly at: 867-5309
1. Opioid prescriptions for chronic pain and overdose: a cohort study. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, Weisner CM, Silverberg MJ, Campbell CI, Psaty BM, Von Korff M. Ann Intern Med. 2010 Jan 19;152(2):85-92.
2. Vital Signs: Overdoses of Prescription Opioid Pain Relievers --- United States, 1999--2008 Weekly November 4, 2011 / 60(43);1487-1492